Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod

Rajiv I. Nijhawan, Jeremy M. Hugh, Achiamah Osei-Tutu

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Increased cases of acquired epidermodysplasia verruciformis (EDV) have been reported in patients with human immunodeficiency virus (HIV). With regard to management, there are no randomized controlled trials in either immunocompetent or immunocompromised patients, and only a limited number of anecdotal treatment options. Systemic retinoids, either independently or in combination with other treatment modalities, have been used with limited success, demonstrating transient clinical response and recurrence of lesions after cessation of therapy. We report a case of an HIV-positive patient with acquired EDV who achieved sustained clinical resolution even after discontinuation of oral acitretin by applying topical imiquimod to prevent recurrence of his lesions.

Original languageEnglish (US)
Pages (from-to)348-349
Number of pages2
JournalJournal of Drugs in Dermatology
Volume12
Issue number3
StatePublished - Mar 1 2013

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod'. Together they form a unique fingerprint.

  • Cite this